ilaprazole + doxycycline + furazolidone + colloidal bismuth tartrate

This is a four-drug combination therapy consisting of ilaprazole, doxycycline, furazolidone, and colloidal bismuth tartrate. It is primarily used for the eradication of *Helicobacter pylori* (H. pylori) infection and the treatment of peptic ulcer disease and related gastrointestinal disorders. - **Ilaprazole** is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+, K+-ATPase enzyme in gastric parietal cells[1][2][5][7]. - **Doxycycline** is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. - **Furazolidone** is a nitrofuran antibacterial agent with additional monoamine oxidase inhibitor (MAOI) activity; it interferes with bacterial enzyme systems and has broad-spectrum activity against bacteria and protozoa[6][8][10]. - **Colloidal bismuth tartrate** acts as a mucosal protective agent with antimicrobial properties against H. pylori. This quadruple regimen targets both acid suppression (ilaprazole), direct bacterial killing (doxycycline, furazolidone), inhibition of protein synthesis in bacteria (doxycycline), disruption of multiple microbial pathways including protozoa (furazolidone), and mucosal protection plus additional anti-H. pylori action from bismuth compounds.